Thursday 16 October, 2025
Objective: Increasing evidence indicates that the contributions of cancer stem-like cells (CSCs) may act as hallmarks of cancer development (1,…
Read morePoster: Drug/Disease modeling - Oncology
Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft
Thursday 16 October, 2025
Objectives: Lung cancer is the most lethal form of cancer in the world (1). Sunitinib is a promising multi-targeted receptor…
Read moreA New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer
Thursday 16 October, 2025
Objectives: : To find new optimized temporal protocols for the combined administration of etoposide/cisplatin for small cell lung cancer (SCLC)…
Read moreModeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer
Thursday 16 October, 2025
Objectives: To develop a biologically-based mathematical model that is capable of describing the impact of adding bevacizumab (B) to chemotherapy…
Read moreMonte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours.
Thursday 16 October, 2025
Objectives: Due to large interpatient variability, therapeutic drug monitoring (TDM) is being considered to individualise cancer treatment with tyrosine kinase…
Read moreA quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions
Thursday 16 October, 2025
Objectives: Targeting of the tumor microenvironment and of immune cell-dependent mechanisms is a promising emerging approach for the treatment of different…
Read morePopulation Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients
Thursday 16 October, 2025
Objectives: Inotuzumab ozogamicin (InO; PF-05208773) is a humanized anti-Cluster of Differentiation 22 (CD22) monoclonal antibody conjugated to calicheamicin, a potent…
Read moreMarkov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients
Thursday 16 October, 2025
Objectives: To develop a population K-PD model for tumour shrinkage effects of first line treatment in patients with locally advanced gastric…
Read morePopulation modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib
Thursday 16 October, 2025
Objectives: Three-dimensional (3D) and density-based tumor metrics have been suggested to better discriminate tumor response to treatment than the traditional…
Read moreModeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F
Thursday 16 October, 2025
Objectives: Reversible transient elevation of alanine aminotransferase (ALT) is observed after intravenous (iv) administration of kahalalide F (KF) in cancer…
Read more